Stock Events

Stock Events

D.Western Therapeutics Institute 

€0.44
0
-€0.02-4.76% Today

Statistics

Day High
0.44
Day Low
0.44
52W High
4.35
52W Low
0.5
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q4 2025
Next
-0.01
0.32
0.65
0.99
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6DW.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is a leading biotech company focusing on the development of medicines for serious medical conditions, directly competing in the biopharmaceutical market.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis and other severe diseases, competing in similar therapeutic areas as D.Western Therapeutics Institute.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences is renowned for its innovative treatments in areas like HIV/AIDS, liver diseases, and oncology, overlapping with D.Western's research interests.
AMGEN
AMGN
Mkt Cap185.74B
Amgen is a global biotechnology firm that develops novel therapies in areas such as oncology and cardiovascular disease, aligning with D.Western's focus areas.
Biogen
BIIB
Mkt Cap27.06B
Biogen focuses on neurology, autoimmune disorders, and rare diseases, competing with D.Western Therapeutics Institute in the biotech innovation sector.
Novartis
NVS
Mkt Cap280.79B
Novartis is a global healthcare company that manufactures drugs that treat various medical conditions, potentially competing across multiple therapeutic areas.
Pfizer
PFE
Mkt Cap153.59B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including those researched by D.Western Therapeutics Institute.
Merck
MRK
Mkt Cap276.38B
Merck & Co. is known for its high-quality pharmaceutical products that target different healthcare challenges, similar to D.Western's market.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca operates in key areas such as oncology, cardiovascular, renal & metabolism, and respiratory, competing in the same spheres as D.Western.
Sanofi
SNY
Mkt Cap112.08B
Sanofi focuses on pharmaceuticals and biopharmaceuticals, particularly in areas like immunology and inflammation, directly competing with D.Western Therapeutics Institute's interests.

About

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
Show more...
CEO
Mr. Yuichi Hidaka
Employees
19
Country
Japan
ISIN
JP3548740004

Listings

STU
DE
6DW.STU
F
DE
6DW.F
TSE
JP
4576.TSE

0 Comments

Share your thoughts

FAQ

What is D.Western Therapeutics Institute stock price today?▼
The current price of 6DW.STU is €0.44 EUR — it has decreased by -4.76% in the past 24 hours. Watch D.Western Therapeutics Institute stock price performance more closely on the chart.
What is D.Western Therapeutics Institute stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange D.Western Therapeutics Institute stocks are traded under the ticker 6DW.STU.
When is the next D.Western Therapeutics Institute earnings date?▼
D.Western Therapeutics Institute is going to release the next earnings report on May 14, 2026.
What were D.Western Therapeutics Institute earnings last quarter?▼
6DW.STU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does D.Western Therapeutics Institute have?▼
As of April 29, 2026, the company has 19 employees.
In which sector is D.Western Therapeutics Institute located?▼
D.Western Therapeutics Institute operates in the Health & Wellness sector.
When did D.Western Therapeutics Institute complete a stock split?▼
D.Western Therapeutics Institute has not had any recent stock splits.
Where is D.Western Therapeutics Institute headquartered?▼
D.Western Therapeutics Institute is headquartered in Nagoya, Japan.